Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Minerva Med ; 88(3): 109-15, 1997 Mar.
Artículo en Italiano | MEDLINE | ID: mdl-9148226

RESUMEN

Twenty patients with cirrhosis and ascites were randomly divided in two groups to receive 20 mg/die of the new-loop-diuretic torasemide (T), and 50 mg/die of furosemide (F). All patients also received 200 mg/die of potassium canrenoate. Natriuretic and diuretic effects and consequent loss of weight were significantly better in the torasemide-group (T-group). Otherwise, loss of potassium and sodium/potassium ratio in urine were not significantly higher for T-group. Ammonium lowered with T and remained unchanged with F, but the difference was not statistically significant. No change was observed in blood-pressure, pulse-frequency, electrolyte plasmatic levels, azotemia, creatininemia and serum albumin. A significant increase of diuresis was obtained from the fourth day of treatment onwards by replacing F with T in the F-group. The T-group maintained T for eight days just to evaluate its efficacy and tolerability in the middle term: diuresis kept efficient and no side-effects occurred. This trial showed that T was a good and handy drug for cirrhosis with ascites whether as an alternative to F, or as a sequential treatment.


Asunto(s)
Ascitis/tratamiento farmacológico , Diuréticos/uso terapéutico , Furosemida/uso terapéutico , Cirrosis Hepática/complicaciones , Sulfonamidas/uso terapéutico , Ascitis/etiología , Ascitis/orina , Femenino , Humanos , Cirrosis Hepática/orina , Masculino , Persona de Mediana Edad , Torasemida
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA